Developer docs
API playgroundTry for free, no card

Search company profiles

Alderley Analytical

Full company profile

uuid0004jc7

Namestring
Alderley Analytical
Legal namestring
Alderley Analytical Ltd.
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Alderley Analytical Ltd. is an independent UK-based bioanalytical Contract Research Organisation founded in 2013/2014 by four scientists (Paul Holme, Claire Wildgoose, Sally Hannam, and a fourth co-founder) and headquartered at Alderley Park in Macclesfield, Cheshire. The firm provides GLP- and GCP-accredited bioanalytical services spanning pre-clinical discovery, pre-clinical regulatory safety, and clinical development, serving pharmaceutical, biotechnology, and other CRO clients globally, with a secondary vertical in agrochemicals via the Concept Life Sciences partnership. Its service portfolio is structured around two pillars — Pre-Clinical Bioanalysis (non-regulatory, GLP regulatory, toxicokinetics, formulation analysis) and Clinical Bioanalysis (GCP regulatory, immunogenicity/ADA, biomarker analysis) — supported by dedicated -80°C/-20°C/4°C/ambient sample storage. The core technology platform integrates mass spectrometry (multiple Waters and Sciex LC-MS/MS systems with UHPLC), ligand binding assays (Molecular Devices EIA/ELISA plate readers and Meso Scale Discovery ECLIA readers for singleplex/multiplex), surface plasmon resonance (SPR) for ADA binding characterisation, and ICP-MS for trace element bioanalysis, with sample data captured and managed in a validated Thermo Fisher WATSON LIMS and storage environments monitored 24/7 by a Contronics environmental monitoring system.

The business operates a fee-for-service, project-based model with bespoke quote pricing and direct consultative sales; clients include large/mid pharma, biotech firms (e.g., Medannex, Infex Therapeutics), peer CROs subcontracting specialised work, and agrochemical firms. Alderley Analytical achieved profitability in March 2017, scaled its mass spectrometry fleet to seven instruments by November 2019, relocated to a doubled 3,200 sq ft laboratory at Tytherington Business Park in June 2023, and was wholly acquired by Netherlands-based Synexa Life Sciences BV (backed by Gilde Healthcare) in October 2024 as part of Synexa's 'buy and build' growth strategy. Post-acquisition, the firm continues to operate under the Alderley Analytical brand with Paul Holme retained as CEO, while gaining access to Synexa's broader biomarker, DNA, RNA, protein, cell, and tissue analysis portfolio.

Short descriptiontext

Alderley Analytical is a UK-based, GLP/GCP-accredited bioanalytical CRO providing mass spectrometry, ligand binding, immunogenicity, and biomarker services to pharmaceutical, biotech, agrochemical and CRO clients from discovery through clinical development. Now a Synexa Life Sciences subsidiary.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMacclesfield, United Kingdom
HQ citystring
Macclesfield
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioanalytical services, contract research organization, mass spectrometry analysis, pharmacokinetic assays, immunogenicity testing
Industry2 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
NAICS code2 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Medical Laboratories8071
Product category
Bioanalytical Contract Research Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1CRO bioanalytical services (project-based)
TypeProfessional Services
Description

Fee-for-service contract research revenue from providing bespoke bioanalytical services to Pharmaceutical, Biotech and CRO clients across discovery, pre-clinical safety testing, and clinical development phases. Services include GLP and GCP regulatory bioanalysis, non-regulatory bioanalysis, biomarker analysis, immunogenicity (ADA), ligand binding assays, formulation analysis, and toxicokinetics. Revenue is generated on a project/quoted basis with retained-client continuity.

alderleyanalytical.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Pricing details2 tiers
1Quote-based bespoke CRO service pricing; no public price list
ModelOtherBilling cadenceMulti-year contract
Notes

No publicly disclosed pricing. Clients must request a quote. Pricing varies by project complexity, regulatory framework (GLP/GCP/non-regulatory), and molecule type (small molecule, peptide, oligonucleotide, biomarker, large molecule).

alderleyanalytical.com
2Non-regulatory bioanalysis with 2 service levels (Level 1 rapid screen vs Level 2 tailored/qualified)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Level 1 is a rapid, low-cost screen with generic methodology. Level 2 is a tailored approach with method qualification (limited validation), used for dose range finding studies; results possible in as little as 3 working days.

alderleyanalytical.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Alderley Analytical is an independent UK-based contract research organisation (CRO) providing specialist bioanalytical services to pharmaceutical, biotech and other CRO clients across discovery, pre-clinical safety testing and clinical development phases. Services include GLP and GCP regulatory bioanalysis, non-regulatory bioanalysis, biomarker analysis, immunogenicity (anti-drug antibody) assays, ligand binding assays, toxicokinetics, formulation analysis and secure sample storage, delivered from a GLP/GCP-accredited laboratory using LC-MS/MS, ligand binding and SPR instrumentation with a validated WATSON LIMS.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Non-regulatory bioanalysis results delivered in as little as 3 working days after sample receipt
+3 more records
Product overview1 text field

Alderley Analytical delivers a unified, end-to-end bioanalytical services portfolio organised as a platform-plus-modules architecture spanning the full drug development lifecycle from discovery through clinical development. The portfolio rests on two core service pillars — Pre-Clinical Bioanalysis and Clinical Bioanalysis — supported by a dedicated Sample Storage service. Pre-Clinical Bioanalysis comprises the modules Non-Regulatory Bioanalysis, GLP Regulatory Bioanalysis, Toxicokinetics, and Formulation Analysis, while Clinical Bioanalysis comprises the modules Immunogenicity, GCP Regulatory Bioanalysis, and Biomarker Analysis. This structure enables clients to retain a single bioanalysis provider across all stages of their programme, eliminating laboratory transfers and loss of molecule-specific bioanalytical knowledge. The services are delivered from Alderley Analytical's laboratories using LC-MS/MS (Waters and Sciex) and ligand-binding assay (Molecular Devices plate readers and MSD readers) instrumentation, with bioanalytical data captured on a validated Thermo Fisher WATSON LIMS. Since October 2024, Alderley Analytical has operated as part of Synexa Life Sciences.

Product and service10 records
1Pre-Clinical Bioanalysis
CategoryCore Service
Description

Full suite of bioanalytical services supporting pre-clinical drug development, covering discovery through regulatory pre-clinical safety studies, including expert handling of microsample volumes and method development/validation in compliance with regulatory guidelines.

2Non-Regulatory Bioanalysis
CategorySub-service (Pre-Clinical module)
Description

Rapid-turnaround bioanalysis via UPLC-MS/MS and ELISA (MSD or colorimetric) for discovery PK, efficacy and DMTA-cycle decision support, offered at two levels — Level 1 rapid low-cost screen with generic methodology, and Level 2 tailored approach with method qualification for tighter data sets — with results possible in as little as 3 working days.

3GLP Regulatory Bioanalysis
CategorySub-service (Pre-Clinical module)
Description

Fully GLP-compliant bioanalytical service for pre-clinical regulatory safety studies, with validated assays meeting MHRA and ICH guidelines, performed under the company's GLP-certified Quality Management System.

4Toxicokinetics
CategorySub-service (Pre-Clinical module)
Description

Generation and interpretation of pharmacokinetic data as an integral component of pre-clinical toxicity studies, describing systemic exposure and its relationship to dose level and time course using validated software.

5Formulation Analysis
CategorySub-service (Pre-Clinical module)
Description

Pre-clinical formulation analysis quantifying achieved concentrations, homogeneity and stability of dose formulations (solutions or suspensions) for GLP toxicology studies, including method development, validation and stability testing.

6Clinical Bioanalysis
CategoryCore Service
Description

Comprehensive clinical bioanalysis providing fully GCP-compliant regulatory service to support bioanalysis of drug molecules through the clinical phase of testing, using highly sensitive instrumentation capable of detecting molecules at very low clinical dose levels.

7Immunogenicity
CategorySub-service (Clinical module)
Description

Anti-drug antibody (ADA) screening, confirmation and titre analysis using a routinely tiered approach, including bridging immunoassays, inhibition confirmation, titration assays, and SPR (surface plasmon resonance) for characterising binding events and drug interference.

8GCP Regulatory Bioanalysis
CategorySub-service (Clinical module)
Description

Fully compliant GCP bioanalytical service to quantify molecules in clinical study biological samples, including Incurred Sample Reanalysis (ISR) where required and LIMS-captured data, supporting PK determination in clinical studies.

9Biomarker Analysis
CategorySub-service (Clinical module)
Description

Biomarker assay development and validation using single and multiplex platforms (MSD or ELISA), applying a 'fit-for-purpose' approach based on the biomarker's context of use, ranging from exploratory to fully quantitative pivotal assays.

10Sample Storage
CategoryCore Service
Description

Dedicated sample storage facility offering -80°C, -20°C, 4°C and ambient temperature storage with 24/7 Contronics environmental monitoring and partner overflow capacity via Cryoniss, including stability assessment and stabiliser development during assay validation.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagship / Parent CompanyTypeStrategic or Co-development PartnerAnnounced on2024-10-03
Description

Netherlands-based Synexa Life Sciences BV acquired Alderley Analytical on 3 October 2024. The acquisition is a key step in Synexa's 'buy and build' growth strategy, with Alderley's LC-MS/MS, biomarker, and bioanalytical capabilities integrated into Synexa's biomarker and bioanalytical assays (DNA, RNA, protein, cell, tissue analysis). Synexa is backed by Gilde Healthcare. Paul Holme remains as CEO of Alderley Analytical within the group; Emile Lens is CEO of Synexa Life Sciences.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership agreement to provide high-value bioanalytical and DMPK study services. Concept gains access to Alderley Analytical's bioanalytical expertise; Alderley benefits from Concept's synthetic/organic/medicinal chemistry, biology, toxicology and analytical services. Combined offering serves biotech, pharma and agrochemical clients. Quote from Michael Fort (Executive Chairman, Concept Life Sciences) and Liz Thomas (CEO, Alderley Analytical).

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Alderley Analytical joined the TherapeutAix global R&D network, forming a dedicated team to solve Pharmacokinetics and Pharmacodynamics (PK/PD) challenges for clients. Partnership supports emerging projects with Alderley's bioanalytical expertise.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Deal for PK and ADA analysis support of Infex's RESP-X program — a humanised monoclonal antibody anti-virulence therapy targeting Pseudomonas aeruginosa infections, in-licensed from Japanese pharma Shionogi. Quotes from Dr Peter Jackson (CEO, Infex) and Liz Thomas (CEO, Alderley Analytical).

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration exploring an alternative COVID-19 testing method. Alderley Analytical provided specialist bioanalytical services and produced data using LC-MS high-throughput targeted proteomics to detect SARS-CoV-2. The collaboration produced a Waters application note on LC-MS detection of MRM-based SARS-CoV-2 analysis.

6Medusa-19
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Alderley Analytical supported the Medusa-19 team in developing their Rapid Saliva Protein Test for COVID-19 detection. No formal partnership terms described.

alderleyanalytical.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multi-year (4+ years) collaboration on challenging assay development projects. Alderley Analytical delivered high quality, robust PK assays and was described as 'an extension of our team' by Dr. Fiona Dempsey, Director of Scientific Operations at Medannex.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Netherlands-based biomarker and bioanalytical CRO and parent company of Alderley Analytical since October 2024. Directly comparable as a specialist bioanalytical/biomarker lab CRO serving pharma and biotech with similar assay-development capabilities.

TypeDirect peer
Description

Specialist bioanalytical CRO focused on large-molecule PK, immunogenicity (ADA) and biomarker assays using LC-MS/MS and ligand binding platforms. Closely comparable in services, modalities served and scientific positioning to Alderley Analytical.

TypeBroad incumbent
Description

UK-headquartered life sciences measurement and testing group with a dedicated bioanalytical/CRO services division offering LC-MS/MS, immunoassay and biomarker support. Overlaps with Alderley on regulated bioanalysis but operates at materially larger scale.

TypeDirect peer
Description

UK-based CRO partner of Alderley Analytical offering combined bioanalytical and DMPK services to pharma, biotech and agrochemical clients. Overlaps directly in bioanalytical assay development, PK analysis and DMPK study support.

TypeBroad incumbent
Description

Global CRO with extensive bioanalytical, PK and immunogenicity capabilities via Eurofins Discovery and BioPharma Product Testing. Comparable on regulated LC-MS/MS and ligand binding services but at much broader portfolio and geographic scale.

TypeBroad incumbent
Description

Large global CRO with a dedicated bioanalytical services division offering LC-MS/MS, immunoassay, ADA and biomarker support across pre-clinical and clinical phases. Direct service overlap with Alderley, though at substantially greater scale.

TypeBroad incumbent
Description

Global CRO with bioanalytical laboratories providing LC-MS/MS, ligand binding, immunogenicity and biomarker services for clinical trials. Comparable bioanalytical offering; senior Alderley BD leadership (Justin Wildgoose) previously worked at ICON, evidencing direct industry overlap.

TypeBroad incumbent
Description

IQVIA-owned central and bioanalytical lab services business providing global LC-MS/MS, immunoassay and biomarker support. Direct overlap on regulated bioanalysis; Justin Wildgoose, Alderley's Director of Business Development, joined from Q2 Solutions' bioanalysis/ADME division.

TypeBroad incumbent
Description

One of the largest global CROs with extensive bioanalytical capabilities across small and large molecules, biomarkers and immunogenicity. Sets the upper-bound competitive benchmark on scale and global footprint for specialist bioanalytical CROs like Alderley.

TypeBroad incumbent
Description

Thermo Fisher-owned global CRO with bioanalytical laboratory services spanning LC-MS/MS, ligand binding and biomarker analysis. Comparable on the regulated bioanalysis side and represents both a partner (WATSON LIMS provider) and competitor for specialist CROs.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Alderley Analytical

Bioanalytical Contract Research Servicesalderleyanalytical.com

Alderley Analytical is a UK-based, GLP/GCP-accredited bioanalytical CRO providing mass spectrometry, ligand binding, immunogenicity, and biomarker services to pharmaceutical, biotech, agrochemical and CRO clients from discovery through clinical development. Now a Synexa Life Sciences subsidiary.

What Alderley Analytical does

Alderley Analytical Ltd. is an independent UK-based bioanalytical Contract Research Organisation founded in 2013/2014 by four scientists (Paul Holme, Claire Wildgoose, Sally Hannam, and a fourth co-founder) and headquartered at Alderley Park in Macclesfield, Cheshire. The firm provides GLP- and GCP-accredited bioanalytical services spanning pre-clinical discovery, pre-clinical regulatory safety, and clinical development, serving pharmaceutical, biotechnology, and other CRO clients globally, with a secondary vertical in agrochemicals via the Concept Life Sciences partnership. Its service portfolio is structured around two pillars — Pre-Clinical Bioanalysis (non-regulatory, GLP regulatory, toxicokinetics, formulation analysis) and Clinical Bioanalysis (GCP regulatory, immunogenicity/ADA, biomarker analysis) — supported by dedicated -80°C/-20°C/4°C/ambient sample storage. The core technology platform integrates mass spectrometry (multiple Waters and Sciex LC-MS/MS systems with UHPLC), ligand binding assays (Molecular Devices EIA/ELISA plate readers and Meso Scale Discovery ECLIA readers for singleplex/multiplex), surface plasmon resonance (SPR) for ADA binding characterisation, and ICP-MS for trace element bioanalysis, with sample data captured and managed in a validated Thermo Fisher WATSON LIMS and storage environments monitored 24/7 by a Contronics environmental monitoring system.

The business operates a fee-for-service, project-based model with bespoke quote pricing and direct consultative sales; clients include large/mid pharma, biotech firms (e.g., Medannex, Infex Therapeutics), peer CROs subcontracting specialised work, and agrochemical firms. Alderley Analytical achieved profitability in March 2017, scaled its mass spectrometry fleet to seven instruments by November 2019, relocated to a doubled 3,200 sq ft laboratory at Tytherington Business Park in June 2023, and was wholly acquired by Netherlands-based Synexa Life Sciences BV (backed by Gilde Healthcare) in October 2024 as part of Synexa's 'buy and build' growth strategy. Post-acquisition, the firm continues to operate under the Alderley Analytical brand with Paul Holme retained as CEO, while gaining access to Synexa's broader biomarker, DNA, RNA, protein, cell, and tissue analysis portfolio.

Alderley Analytical firmographics

Firmographics
Name
Alderley Analytical
Legal name
Alderley Analytical Ltd.
Website
https://alderleyanalytical.com
Company type
Private
Founded year
2013
Operating status
Acquired
Headcount range
11–50 employees
Short description
Alderley Analytical is a UK-based, GLP/GCP-accredited bioanalytical CRO providing mass spectrometry, ligand binding, immunogenicity, and biomarker services to pharmaceutical, biotech, agrochemical and CRO clients from discovery through clinical development. Now a Synexa Life Sciences subsidiary.
Ownership category
akta.pro rank

Alderley Analytical industry classification

Industry
Product category
Bioanalytical Contract Research Services
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs

Keywords

  • Bioanalytical services
  • Contract research organization
  • Mass spectrometry analysis
  • Pharmacokinetic assays
  • Immunogenicity testing

Where Alderley Analytical is headquartered

Location

Headquarters

HQ city
Macclesfield
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

Alderley Analytical business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. CRO bioanalytical services (project-based): Fee-for-service contract research revenue from providing bespoke bioanalytical services to Pharmaceutical, Biotech and CRO clients across discovery, pre-clinical safety testing, and clinical development phases. Services include GLP and GCP regulatory bioanalysis, non-regulatory bioanalysis, biomarker analysis, immunogenicity (ADA), ligand binding assays, formulation analysis, and toxicokinetics. Revenue is generated on a project/quoted basis with retained-client continuity.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractQuote-based bespoke CRO service pricing; no public price list
Unit PricingPay-as-you-goNon-regulatory bioanalysis with 2 service levels (Level 1 rapid screen vs Level 2 tailored/qualified)

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Alderley Analytical product offering

Product offering

Core offering

Alderley Analytical is an independent UK-based contract research organisation (CRO) providing specialist bioanalytical services to pharmaceutical, biotech and other CRO clients across discovery, pre-clinical safety testing and clinical development phases. Services include GLP and GCP regulatory bioanalysis, non-regulatory bioanalysis, biomarker analysis, immunogenicity (anti-drug antibody) assays, ligand binding assays, toxicokinetics, formulation analysis and secure sample storage, delivered from a GLP/GCP-accredited laboratory using LC-MS/MS, ligand binding and SPR instrumentation with a validated WATSON LIMS.

Product overview

Alderley Analytical delivers a unified, end-to-end bioanalytical services portfolio organised as a platform-plus-modules architecture spanning the full drug development lifecycle from discovery through clinical development. The portfolio rests on two core service pillars — Pre-Clinical Bioanalysis and Clinical Bioanalysis — supported by a dedicated Sample Storage service. Pre-Clinical Bioanalysis comprises the modules Non-Regulatory Bioanalysis, GLP Regulatory Bioanalysis, Toxicokinetics, and Formulation Analysis, while Clinical Bioanalysis comprises the modules Immunogenicity, GCP Regulatory Bioanalysis, and Biomarker Analysis. This structure enables clients to retain a single bioanalysis provider across all stages of their programme, eliminating laboratory transfers and loss of molecule-specific bioanalytical knowledge. The services are delivered from Alderley Analytical's laboratories using LC-MS/MS (Waters and Sciex) and ligand-binding assay (Molecular Devices plate readers and MSD readers) instrumentation, with bioanalytical data captured on a validated Thermo Fisher WATSON LIMS. Since October 2024, Alderley Analytical has operated as part of Synexa Life Sciences.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pre-Clinical Bioanalysis Full suite of bioanalytical services supporting pre-clinical drug development, covering discovery through regulatory pre-clinical safety studies, including expert handling of microsample volumes and method development/validation in compliance with regulatory guidelines.
  • Non-Regulatory Bioanalysis Rapid-turnaround bioanalysis via UPLC-MS/MS and ELISA (MSD or colorimetric) for discovery PK, efficacy and DMTA-cycle decision support, offered at two levels — Level 1 rapid low-cost screen with generic methodology, and Level 2 tailored approach with method qualification for tighter data sets — with results possible in as little as 3 working days.
  • GLP Regulatory Bioanalysis Fully GLP-compliant bioanalytical service for pre-clinical regulatory safety studies, with validated assays meeting MHRA and ICH guidelines, performed under the company's GLP-certified Quality Management System.
  • Toxicokinetics Generation and interpretation of pharmacokinetic data as an integral component of pre-clinical toxicity studies, describing systemic exposure and its relationship to dose level and time course using validated software.
  • Formulation Analysis Pre-clinical formulation analysis quantifying achieved concentrations, homogeneity and stability of dose formulations (solutions or suspensions) for GLP toxicology studies, including method development, validation and stability testing.
  • Clinical Bioanalysis Comprehensive clinical bioanalysis providing fully GCP-compliant regulatory service to support bioanalysis of drug molecules through the clinical phase of testing, using highly sensitive instrumentation capable of detecting molecules at very low clinical dose levels.
  • Immunogenicity Anti-drug antibody (ADA) screening, confirmation and titre analysis using a routinely tiered approach, including bridging immunoassays, inhibition confirmation, titration assays, and SPR (surface plasmon resonance) for characterising binding events and drug interference.
  • GCP Regulatory Bioanalysis Fully compliant GCP bioanalytical service to quantify molecules in clinical study biological samples, including Incurred Sample Reanalysis (ISR) where required and LIMS-captured data, supporting PK determination in clinical studies.
  • Biomarker Analysis Biomarker assay development and validation using single and multiplex platforms (MSD or ELISA), applying a 'fit-for-purpose' approach based on the biomarker's context of use, ranging from exploratory to fully quantitative pivotal assays.
  • Sample Storage Dedicated sample storage facility offering -80°C, -20°C, 4°C and ambient temperature storage with 24/7 Contronics environmental monitoring and partner overflow capacity via Cryoniss, including stability assessment and stabiliser development during assay validation.

Quantifiable outcome

  • Non-regulatory bioanalysis results delivered in as little as 3 working days after sample receipt
  • +3 more outcomes

Companies that use Alderley Analytical

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Alderley Analytical technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

Feature7 records

Alderley Analytical partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship / parent company, core and minor.

  • Synexa Life Sciencesflagship / parent companyStrategic or Co-development Partner · 3 October 2024Netherlands-based Synexa Life Sciences BV acquired Alderley Analytical on 3 October 2024. The acquisition is a key step in Synexa's 'buy and build' growth strategy, with Alderley's LC-MS/MS, biomarker, and bioanalytical capabilities integrated into Synexa's biomarker and bioanalytical assays (DNA, RNA, protein, cell, tissue analysis). Synexa is backed by Gilde Healthcare. Paul Holme remains as CEO of Alderley Analytical within the group; Emile Lens is CEO of Synexa Life Sciences.
  • Concept Life SciencescoreStrategic or Co-development PartnerPartnership agreement to provide high-value bioanalytical and DMPK study services. Concept gains access to Alderley Analytical's bioanalytical expertise; Alderley benefits from Concept's synthetic/organic/medicinal chemistry, biology, toxicology and analytical services. Combined offering serves biotech, pharma and agrochemical clients. Quote from Michael Fort (Executive Chairman, Concept Life Sciences) and Liz Thomas (CEO, Alderley Analytical).
  • TherapeutAixminorStrategic or Co-development PartnerAlderley Analytical joined the TherapeutAix global R&D network, forming a dedicated team to solve Pharmacokinetics and Pharmacodynamics (PK/PD) challenges for clients. Partnership supports emerging projects with Alderley's bioanalytical expertise.
  • Infex TherapeuticsminorStrategic or Co-development PartnerDeal for PK and ADA analysis support of Infex's RESP-X program — a humanised monoclonal antibody anti-virulence therapy targeting Pseudomonas aeruginosa infections, in-licensed from Japanese pharma Shionogi. Quotes from Dr Peter Jackson (CEO, Infex) and Liz Thomas (CEO, Alderley Analytical).
  • University of Leicester, Ghent University and Waters CorporationminorStrategic or Co-development PartnerCollaboration exploring an alternative COVID-19 testing method. Alderley Analytical provided specialist bioanalytical services and produced data using LC-MS high-throughput targeted proteomics to detect SARS-CoV-2. The collaboration produced a Waters application note on LC-MS detection of MRM-based SARS-CoV-2 analysis.
  • Medusa-19minorStrategic or Co-development PartnerAlderley Analytical supported the Medusa-19 team in developing their Rapid Saliva Protein Test for COVID-19 detection. No formal partnership terms described.
  • MedannexcoreStrategic or Co-development PartnerMulti-year (4+ years) collaboration on challenging assay development projects. Alderley Analytical delivered high quality, robust PK assays and was described as 'an extension of our team' by Dr. Fiona Dempsey, Director of Scientific Operations at Medannex.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Alderley Analytical competitors and assessment

Company assessment

Direct peers

  • Synexa Life Sciences: Netherlands-based biomarker and bioanalytical CRO and parent company of Alderley Analytical since October 2024. Directly comparable as a specialist bioanalytical/biomarker lab CRO serving pharma and biotech with similar assay-development capabilities.
  • BioAgilytix Labs: Specialist bioanalytical CRO focused on large-molecule PK, immunogenicity (ADA) and biomarker assays using LC-MS/MS and ligand binding platforms. Closely comparable in services, modalities served and scientific positioning to Alderley Analytical.
  • Concept Life Sciences: UK-based CRO partner of Alderley Analytical offering combined bioanalytical and DMPK services to pharma, biotech and agrochemical clients. Overlaps directly in bioanalytical assay development, PK analysis and DMPK study support.

Broad incumbents

  • LGC Group (Bioanalytical Services): UK-headquartered life sciences measurement and testing group with a dedicated bioanalytical/CRO services division offering LC-MS/MS, immunoassay and biomarker support. Overlaps with Alderley on regulated bioanalysis but operates at materially larger scale.
  • Eurofins Bioanalytical Services: Global CRO with extensive bioanalytical, PK and immunogenicity capabilities via Eurofins Discovery and BioPharma Product Testing. Comparable on regulated LC-MS/MS and ligand binding services but at much broader portfolio and geographic scale.
  • Charles River Laboratories: Large global CRO with a dedicated bioanalytical services division offering LC-MS/MS, immunoassay, ADA and biomarker support across pre-clinical and clinical phases. Direct service overlap with Alderley, though at substantially greater scale.
  • ICON plc: Global CRO with bioanalytical laboratories providing LC-MS/MS, ligand binding, immunogenicity and biomarker services for clinical trials. Comparable bioanalytical offering; senior Alderley BD leadership (Justin Wildgoose) previously worked at ICON, evidencing direct industry overlap.
  • Q2 Solutions (IQVIA): IQVIA-owned central and bioanalytical lab services business providing global LC-MS/MS, immunoassay and biomarker support. Direct overlap on regulated bioanalysis; Justin Wildgoose, Alderley's Director of Business Development, joined from Q2 Solutions' bioanalysis/ADME division.
  • Labcorp Drug Development (Covance): One of the largest global CROs with extensive bioanalytical capabilities across small and large molecules, biomarkers and immunogenicity. Sets the upper-bound competitive benchmark on scale and global footprint for specialist bioanalytical CROs like Alderley.
  • Thermo Fisher Scientific PPD: Thermo Fisher-owned global CRO with bioanalytical laboratory services spanning LC-MS/MS, ligand binding and biomarker analysis. Comparable on the regulated bioanalysis side and represents both a partner (WATSON LIMS provider) and competitor for specialist CROs.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Alderley Analytical social profiles

Digital presence

Alderley Analytical compliance and trust

Trust signal

Compliance3 records

Alderley Analytical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Alderley Analytical leadership team

Management profile

Number of profiles

Profiles10 records

Alderley Analytical subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Alderley Analytical funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Alderley Analytical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alderley Analytical

What does Alderley Analytical do?

Alderley Analytical is an independent UK-based contract research organisation (CRO) providing specialist bioanalytical services to pharmaceutical, biotech and other CRO clients across discovery, pre-clinical safety testing and clinical development phases. Services include GLP and GCP regulatory bioanalysis, non-regulatory bioanalysis, biomarker analysis, immunogenicity (anti-drug antibody) assays, ligand binding assays, toxicokinetics, formulation analysis and secure sample storage, delivered from a GLP/GCP-accredited laboratory using LC-MS/MS, ligand binding and SPR instrumentation with a validated WATSON LIMS.

Is Alderley Analytical a public or private company?

Alderley Analytical is a private company. It is classified as corporate owned and is currently acquired.

When was Alderley Analytical founded?

Alderley Analytical was founded in 2013. It employs 11 to 50 people.

Where is Alderley Analytical based?

Alderley Analytical is headquartered in Macclesfield, United Kingdom, in the Europe region.

How does Alderley Analytical make money?

One revenue line is on record: CRO bioanalytical services (project-based).

Who are Alderley Analytical's main competitors?

Direct peers on record are Synexa Life Sciences, BioAgilytix Labs and Concept Life Sciences. Broad incumbents are LGC Group (Bioanalytical Services), Eurofins Bioanalytical Services, Charles River Laboratories, ICON plc, Q2 Solutions (IQVIA), Labcorp Drug Development (Covance) and Thermo Fisher Scientific PPD.

Does Alderley Analytical have an API?

No public API is recorded for Alderley Analytical.

What industry is Alderley Analytical in?

Alderley Analytical's product category is Bioanalytical Contract Research Services. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGAAAE, Central Laboratory & Clinical Trial Testing CROs. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
openPR.comAnalysis of Key Market Segments Driving the Large Molecule Bioanalytical Technologies MarketThe large molecule bioanalytical technologies market is projected to reach $21.22 billion by 2030, growing at a compound annual growth rate of 12.2%, driven by rising monoclonal antibody pipelines, cell and gene therapy research, and increased outsourcing to contract research organizations. In October 2024, Netherlands-based Synexa Life Sciences completed the acquisition of UK-based Alderley Analytical Ltd to strengthen its large-molecule bioanalysis capabilities, including LC-MS/MS, ligand-binding assays, and immunogenicity testing services. Advanced technologies such as hospital-site sterile 3D printing are also emerging as growth drivers, exemplified by 3D Systems' FDA-cleared VSP PEEK Cranial Implant introduced in April 2024.openPR.comBiologics Testing Market Overview, Key Trends, and Insights on Major PlayersThe biologics testing market is projected to grow to $15.07 billion by 2030 with a 17.2% compound annual growth rate, driven by demand for rapid release testing, automated quality control systems, and increasing testing needs for cell and gene therapies. In October 2024, Netherlands-based Synexa Life Sciences acquired UK-based Alderley Analytical Ltd to strengthen its bioanalytical testing capabilities across mass spectrometry and ligand-binding platforms. Additionally, German biotech firm Singleron Biotechnologies GmbH launched two new instruments in June 2023 to optimize single-cell analysis workflows for cell therapy development.BusinessCloudRiver Capital exits Alderley Analytical to European firmAlderley Analytical, a bioanalytical services firm, was acquired by Dutch firm Synexa Life Sciences, backed by Gilde Healthcare. The company, which employed about 60 staff and served over 200 clients, relocated to Tytherington Business Park. River Capital's initial six-figure investment in 2015 has returned more than four times its funding.AlderleyanalyticalSynexa Life Sciences Acquires Alderley AnalyticalSynexa Life Sciences has acquired Alderley Analytical. This acquisition represents a strategic move to enhance Synexa's capabilities in the analytical services sector. The deal is part of Synexa's broader strategy to expand its service offerings and market presence.